Logo-apb
Adv Pharm Bull. Inpress.
doi: 10.34172/apb.2024.034
  Abstract View: 127

Review Article

The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management

Dito Anurogo ORCID logo, Dewi Luthfiana, Nuralfin Anripa ORCID logo, Apriliani Ismi Fauziah, Maratu Soleha, Laila Rahmah, Hana Ratnawati, Teresa Liliana Wargasetia, Sari Eka Pratiwi, Riswal Nafi Siregar, Ratis Nour Sholichah, Yu Hsiang Chang, Taruna Ikrar*, Jiantai Timothy Qiu* ORCID logo, Muhammad Sobri Maulana ORCID logo
*Corresponding Author: Department of Pharmacology, Faculty of Medicine, Malahayati University, Bandar Lampung, Indonesia, Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan, ROC., email: jtqiu1010@tmu.edu.tw Email dr.ikrar.phd@gmail.com, jtqiu1010@tmu.edu.tw
*Corresponding Authors: Email: dr.ikrar.phd@gmail.com; Email: jtqiu1010@tmu.edu.tw

Abstract

Purpose: Lymphoma, the most predominant neoplastic disorder, is divided into Hodgkin and Non-Hodgkin Lymphoma classifications. Immunotherapeutic modalities have emerged as essential methodologies in combating lymphoid malignancies. Chimeric Antigen Receptor (CAR) T cells exhibit promising responses in chemotherapy-resistant B-cell non-Hodgkin lymphoma cases. Methods: This comprehensive review delineates the advancement of CAR-T cell therapy as an immunotherapeutic instrument, the selection of lymphoma antigens for CAR-T cell targeting, and the conceptualization, synthesis, and deployment of CAR-T cells. Furthermore, it encompasses the advantages and disadvantages of CAR-T cell therapy and the prospective horizons of CAR-T cells from a computational research perspective. In order to improve the design and functionality of artificial CARs, there is a need for TCR recognition investigation, followed by the implementation of a quality surveillance methodology. Results: Various lymphoma antigens are amenable to CAR-T cell targeting, such as CD19, CD20, CD22, CD30, the kappa light chain, and ROR1. A notable merit of CAR-T cell therapy is the augmentation of the immune system's capacity to generate tumoricidal activity in patients exhibiting chemotherapy-resistant lymphoma. Nevertheless, it also introduces manufacturing impediments that are laborious, technologically demanding, and financially burdensome. Physical, physicochemical, and physiological limitations further exacerbate the challenge of treating solid neoplasms with CAR-T cells. Conclusion: While the efficacy and safety of CAR-T cell immunotherapy remain subjects of fervent investigation, the promise of this cutting-edge technology offers valuable insights for the future evolution of lymphoma treatment management approaches. Moreover, CAR-T cell therapies potentially benefit patients, motivating regulatory bodies to foster international collaboration.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 124

Your browser does not support the canvas element.


PDF Download: 0

Your browser does not support the canvas element.

Submitted: 17 Mar 2023
Revision: 13 Jan 2024
Accepted: 03 Mar 2024
ePublished: 10 Mar 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)